STOCKWATCH

Gland Pharma Ltd Receives EIR from US FDA for JNPC Facility in Visakhapatnam

Gland Pharma Ltd has announced the receipt of the Establishment Inspection Report (EIR) from the US FDA for their sterile APIs facility at JNPC, Visakhapatnam. This comes after a Pre-approval inspection conducted between February 19, 2025, and February 25, 2025. The EIR indicates the closure of the inspection, which suggests a positive outcome for the company.

• Gland Pharma Ltd receives EIR from US FDA for their sterile APIs facility at JNPC, Visakhapatnam.
• The receipt of the EIR follows a Pre-approval inspection conducted between February 19, 2025, and February 25, 2025.
• The EIR indicates the closure of the inspection, suggesting a positive outcome for the company.